Human-AI-T manifesto takes center stage at Davos 2026 as WISeKey pushes global standards for trusted artificial intelligence
Find out how WISeKey’s Human-AI-T Manifesto unveiled at Davos 2026 is redefining AI trust, digital identity, and global governance standards.
New York Stock Exchange enters tokenization race with regulated blockchain platform for traditional securities
Find out how the New York Stock Exchange is entering the tokenization race with a regulated blockchain platform for traditional securities.
How the U.S. multicloud shift is accelerating Oracle’s rise as a hyperscaler alternative
Find out how the U.S. multicloud shift is accelerating Oracle’s rise as a hyperscaler alternative and reshaping enterprise cloud strategies today.
Modular housing momentum builds as Fab-Form Industries secures high-value White Rock real estate
Discover how Fab-Form Industries’ White Rock property acquisition could accelerate innovative housing solutions and reshape investor expectations.
Nexus Uranium strengthens domestic uranium pipeline with RC claims acquisition in South Dakota
Find out how Nexus Uranium is strengthening its domestic uranium strategy with a new South Dakota claims acquisition and what it means for investors.
Positive early Phase 2 data strengthen Ocugen’s case for OCU410 in the fast-evolving dry AMD treatment market
Find out how Ocugen’s early Phase 2 data for OCU410 could reshape competition and investor sentiment in the fast-growing dry AMD treatment market.
Genetic stratification reframes HMNC Brain Health’s BH-200 Phase 2b data and revives precision psychiatry strategy at ACNP
Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reframed clinical risk and revived precision psychiatry strategy in depression.
AGAMREE wins Swissmedic approval, positioning Santhera for broader Duchenne muscular dystrophy market expansion
Santhera wins Swissmedic approval for AGAMREE in Duchenne muscular dystrophy. Find out how this milestone could drive European expansion and investor sentiment.
AAVantgarde clears key execution hurdle as LUCE-1 Phase 1/2 study of AAVB-081 completes enrollment
Find out how AAVantgarde Bio’s LUCE-1 enrollment milestone reshapes the gene therapy landscape for Usher syndrome type B retinitis pigmentosa.
Vaxart advances oral vaccine platform with positive maternal and infant data from norovirus study
Find out how Vaxart advanced its oral vaccine platform with positive norovirus data showing maternal immune responses and antibody transfer to infants.